Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Sep 18;10(9):1126.
doi: 10.3390/antibiotics10091126.

Review of Ceftazidime-Avibactam for the Treatment of Infections Caused by Pseudomonas aeruginosa

George L Daikos  1 , Clóvis Arns da Cunha  2 , Gian Maria Rossolini  3   4 , Gregory G Stone  5 , Nathalie Baillon-Plot  6 , Margaret Tawadrous  5 , Paurus Irani  7
Affiliations
Review

Review of Ceftazidime-Avibactam for the Treatment of Infections Caused by Pseudomonas aeruginosa

George L Daikos et al. Antibiotics (Basel). .

Abstract

Pseudomonas aeruginosa is an opportunistic Gram-negative pathogen that causes a range of serious infections that are often challenging to treat, as this pathogen can express multiple resistance mechanisms, including multidrug-resistant (MDR) and extensively drug-resistant (XDR) phenotypes. Ceftazidime-avibactam is a combination antimicrobial agent comprising ceftazidime, a third-generation semisynthetic cephalosporin, and avibactam, a novel non-β-lactam β-lactamase inhibitor. This review explores the potential role of ceftazidime-avibactam for the treatment of P. aeruginosa infections. Ceftazidime-avibactam has good in vitro activity against P. aeruginosa relative to comparator β-lactam agents and fluoroquinolones, comparable to amikacin and ceftolozane-tazobactam. In Phase 3 clinical trials, ceftazidime-avibactam has generally demonstrated similar clinical and microbiological outcomes to comparators in patients with complicated intra-abdominal infections, complicated urinary tract infections or hospital-acquired/ventilator-associated pneumonia caused by P. aeruginosa. Although real-world data are limited, favourable outcomes with ceftazidime-avibactam treatment have been reported in some patients with MDR and XDR P. aeruginosa infections. Thus, ceftazidime-avibactam may have a potentially important role in the management of serious and complicated P. aeruginosa infections, including those caused by MDR and XDR strains.

Keywords: Pseudomonas aeruginosa; ceftazidime–avibactam; complicated intra-abdominal infection; complicated urinary tract infection; hospital-acquired pneumonia; multidrug resistance.

PubMed Disclaimer

Conflict of interest statement

G.L.D. reports grants and personal fees from Pfizer, personal fees from Achaogen, personal fees from MSD, personal fees from Rempex and personal fees from Menarini, outside the submitted work. C.A.d.C. reports grants and/or personal fees for international clinical trials, advisory boards, speaking and consultancies from Pfizer, Merck (MSD), Janssen Pharmaceuticals Inc. (Janssen Cilag), Novartis, Bayer, Eurofarma, Cerexa, GSK, Sanofi Aventis and AstraZeneca. G.M.R. has received research grants and/or been a consultant and/or received a fee for speaking from Achaogen, Arrow, Becton-Dickinson, bioMérieux, Checkpoints, Cubist, Curetis, Zambon, Basilea, Cepheid, Accelerate, Merck, Menarini, Nordic Pharma, Elitech, Qiagen, Angelini, Thermo Fisher, Biotest, Pfizer, Astra Zeneca, Rempex, Qpex, Roche, Seegene, Beckman Coulter, Shionogi, VenatorX and Nurex. P.I., G.G.S., N.B.-P. and M.T. are employees of and shareholders in Pfizer.

References

    1. Magill S.S., O’Leary E., Janelle S.J., Thompson D.L., Dumyati G., Nadle J., Wilson L.E., Kainer M.A., Lynfield R., Greissman S., et al. Emerging Infections Program Hospital Prevalence Survey Team. Changes in prevalence of health care-associated infections in U.S. hospitals. N. Engl. J. Med. 2018;379:1732–1744. doi: 10.1056/NEJMoa1801550. - DOI - PMC - PubMed
    1. Rhodes N.J., Cruce C.E., O’Donnell J.N., Wunderink R.G., Hauser A.R. Resistance trends and treatment options in Gram-negative ventilator-associated pneumonia. Curr. Infect. Dis. Rep. 2018;20:3. doi: 10.1007/s11908-018-0609-x. - DOI - PMC - PubMed
    1. Weiner L.M., Webb A.K., Limbago B., Dudeck M.A., Patel J., Kallen A.J., Edwards J.R., Sievert D.M. Antimicrobial-resistant pathogens associated with healthcare-associated infections: Summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2011–2014. Infect. Control Hosp. Epidemiol. 2016;37:1288–1301. doi: 10.1017/ice.2016.174. - DOI - PMC - PubMed
    1. Liu J.Y., Wu Y.H., Cai M., Zhou C.L. Point-prevalence survey of healthcare-associated infections in Beijing, China: A survey and analysis in 2014. J. Hosp. Infect. 2016;93:271–279. doi: 10.1016/j.jhin.2016.03.019. - DOI - PubMed
    1. Sadikot R.T., Blackwell T.S., Christman J.W., Prince A.S. Pathogen-host interactions in Pseudomonas aeruginosa pneumonia. Am. J. Respir. Crit. Care Med. 2005;171:1209–1223. doi: 10.1164/rccm.200408-1044SO. - DOI - PMC - PubMed

LinkOut - more resources